Fundraising Fox

Indapta Therapeutics

Houston, US · Delaware corporation · 3 known investors

Find your way into Indapta Therapeutics

137 people in our graph share verified history with the Indapta Therapeutics team — schools, employers, funds. One of them is your warm intro.

Mira Chaurushiyaunlockedknows Guy DiPierro · together at Chrono Therapeutics (overlapped)
×5knows the team · via Fordham University School of Law
×6knows the team · via University at Albany

Indapta Therapeutics develops an off-the-shelf, allogeneic FcRγ-deficient natural killer (g-NK) cell therapy derived from healthy donors to treat cancer and autoimmune diseases. Its lead candidate IDP-023 is being tested in clinical trials for indications such as multiple myeloma, non-Hodgkin's lymphoma, and progressive multiple sclerosis.

BiotechHealthtech

Founders & leadership

GDGuy DiPierro
Guy DiPierroinChief Operating Officer and FounderGuy DiPierro is Chief Operating Officer and co-founder of Indapta Therapeutics, which develops allogeneic natural killer cell therapy for cancer and autoimmune diseases. He has over 16 years of experience in specialty pharmaceuticals, previously served as Executive Vice President and General Counsel at AMGI Capital, and worked as an attorney in corporate M&A and technology licensing at Sidley Austin and Hogan and Hartson.
SK
Sungjin KimScientific Founder
JS
John SunwooScientific Founder
MWMark W. Frohlich
Mark W. FrohlichChief Executive Officer
SM
Stefanie Mandl-CashmanActing Chief Scientific Officer

Board

LH
Lori HuBoard director
FP
Fabio PucciBoard director
LS
Laura StoppelBoard director
RM
Ronald MartellChairman of the Board and Co-Founder

Investors · 3

Leaps by Bayer✓ verifiedLeverkusen
RA Capital✓ verifiedBoston
Vertex Ventures HC✓ verifiedSingapore · $500K – $10M

Reported raises · per SEC filings

Form D private placements

$84.4M disclosed across 2 of 3 rounds · 2022–2025

▶$50.8MraisedOct 2025 · 46 investors · Other Technology
Rule 506(b)
Officers, directors & promoters on the filing
  • Lori HuDirector
  • Fabio PucciDirector
  • Ronald MartellDirector
  • Mark FrohlichExecutive Officer, Director
Offering amount
$51.6M
Amount sold
$50.8M
First sale
Sep 2025
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$33.6MraisedFeb 2022 · 37 investors · Other Technology
Rule 506(b)
Officers, directors & promoters on the filing
  • Mark FrohlichExecutive Officer, Director
  • Ronald MartellDirector
  • Fabio PucciDirector
  • Laura StoppelDirector
  • Guy DiPierroExecutive Officer
  • Lori HuDirector
Offering amount
$67.1M
Amount sold
$33.6M
Sales commissions
$2.4M
First sale
Jan 2022
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Founder mafia

2 people who came through Indapta Therapeutics went on to found or lead other companies.

Ronald MartellCo-Founder, Executive ChairmanFounded Encellin +3Guy DiPierroChief Operating Officer & Co-FounderFounded Chrono Therapeutics

Competitors · 1

by search overlap
Bioworld13 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.

Companies competing with Indapta Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.

In the news

UH Tech Bridge Community Member Indapta Therapeutics Advances Clinical Trials with $22.5M Funding | University of Houstonuh.edu · May 2025Indapta Therapeutics Secures $22.5 Million to Advance Clinical Trials of Innovative Cancer and Autoimmune Treatments - MMRFthemmrf.org · Dec 2024Indapta Therapeutics Raises $22.5M in Fundingfinsmes.com · Dec 2024Medpathtrial.medpath.com · Dec 2024Indapta Therapeutics | Myeloma Investment Fundmyelomainvestmentfund.org · Dec 2024Indapta Therapeutics Raises $50 Million, Names CEO - Global Genesglobalgenes.org · Feb 2022

Frequently asked questions

What does Indapta Therapeutics do?
Indapta Therapeutics develops an off-the-shelf, allogeneic FcRγ-deficient natural killer (g-NK) cell therapy derived from healthy donors to treat cancer and autoimmune diseases. Its lead candidate IDP-023 is being tested in clinical trials for indications such as multiple myeloma, non-Hodgkin's lymphoma, and progressive multiple sclerosis.
Who founded Indapta Therapeutics?
Indapta Therapeutics was founded by Guy DiPierro, Sungjin Kim, John Sunwoo.
Who are Indapta Therapeutics's investors?
Indapta Therapeutics's investors include Leaps by Bayer, RA Capital, Vertex Ventures HC.
How much funding has Indapta Therapeutics raised?
Indapta Therapeutics has disclosed $84.4M raised across 2 of its 3 known rounds.
Where is Indapta Therapeutics headquartered?
Indapta Therapeutics is headquartered in Houston, US.